News

Progression to type 1 diabetes in autoantibody-positive children could be slowed by increased physical activity | Image Credit: © Drazen - © Drazen - stock.adobe.com.

Results of the study, which was an analysis of accelerometry data the TEDDY study, indicate every 10-minute increase in daily moderate to vigorous physical activity was associated with an 8% reduction in risk of progressing to type 1 diabetes, but this association was not present among those who were single islet autoantibody-positive or single islet autoantibody-negative.

Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California | Image provided

In this Contemporary Pediatrics® interview, Benjamin Maxwell, MD, chief of child and adolescent psychiatry, Rady Children’s Hospital, San Diego, California, details the rise in pediatric mental health concerns, emergency department visits, and the potentially concerning aspects of social media among youth.

FDA approves B-VEC to treat dystrophic epidermolysis bullosa patients 6 months and older | Image Credit: bankrx - Image Credit: bankrx - stock.adobe.com.

The FDA has approved Krystal Biotech's beremagene geperpavec (B-VEC) (Vyjuvek; Krystal Biotech) to treat the wounds of dystrophic epidermolysis bullosa (DEB) patients aged 6 months and older. B-VEC is the first FDA-approved gene therapy treatment for DEB, according to the agency. In this Contemporary Pediatrics interview, Raj Chovatiya, MD, PhD, breaks down this much-anticipated FDA approval.